Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: AbbVie
Condition: Small Cell Lung Cancer
NCT02674568
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | few_sites_large_trial_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.